semaglutide by novo nordisk Novo's Ozempic wins FDA nod to curb kidney disease risks Novo Nordisk takes legal action

Another study, published in The Lancet, found that body weight and body composition were maintained one year after the termination of GLP-1 medications through the use of supervised exercise, in contrast to weight regain after the termination of treatment with obesity pharmacotherapy alone

The Link Between Ozempic and Gastroparesis Recent medical studies have revealed a troubling connection between Ozempic and gastroparesisa condition where the stomachs ability to empty is significantly slowed, leading to chronic digestive issues

Coronary artery spasm: Current knowledge and residual uncertainties

With strong shelf appeal, repeat-purchase potential, and relevance across key wellness categories, it is built to support both customer success and long-term retail performance